IIAM now provides livers for therapeutic uses and pre-clinical investigations. These efforts are intended to treat patients with advanced cirrhosis and those with rare metabolic disorders, targeting Phenylketonuria (PKU), Alpha-1 antitrypsin deficiency (A1AD) and urea cycle disorders. These diseases are identified by the FDA as having minimal treatment options.
This year, IIAM marked a decade of conducting Research Recovery Workshops. Designed to train OPO staff in best surgical practices for organ and tissue recovery, these biannual events have been directly responsible for a dramatic rise in the number and percentage of usable organs and tissue for medical research — especially since 2010.
Not long ago, the prospect of creating artificial organs bordered on science fiction. Due to the efforts of bioengineering research companies like Samsara Sciences and Organovo, that fantasy is coming closer to reality.
Over the past year, Donor Network of Arizona (DNA) has seen a dramatic increase in referrals for non-transplantable organs and tissue for research. As of the end of August, the OPO, located in Phoenix, AZ, had referred 198 organs. At that rate, DNA would reach 300 referrals, compared to 203 in all of 2015.
IIAM is pleased to introduce the newest additions to our Placement Coordinator team, all of whom were hired in 2016. With the volume of referrals from OPOs steadily increasing, this expansion ensures that IIAM can offer full service and eliminate lag time by promptly activating screening and placement of organs and tissue for research.
Many families who receive a non-survivable diagnosis for their baby during pregnancy inquire about organ donation. Too often, they're told there are no options. In 2012, with the commitment of an exceptional couple, a team of OPO staff and medical professionals, IIAM helped shatter that perception.
Bethany Conkel Helps Raise Awareness for Neonatal Donation.